Colorectal Cancer

Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed surgical and medical oncology developments in the colorectal cancer field.

Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.

Panelists offer concluding perspectives on the future role of circulating tumor DNA in colorectal cancer management.

CytoDyn intends to submit its final study protocol to the FDA, engage a clinical research organization, and complete preparatory work to initiate the phase 2 trial.

Managing high-grade squamous intraepithelial lesions may reduce the risk of anal cancer based on data from the phase 3 ANCHOR trial.

Medical professionals analyze gaps in current colorectal cancer patient care, with a focus on minimal residual disease testing.

The panel examines challenges in interpreting circulating tumor DNA results and their impact on clinical decision-making processes.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, share their key takeaways on the clinical utility of ctDNA in the treatment of patients with colorectal cancer.

Experts on colorectal cancer brainstorm ways to optimize clinical research on ctDNA and discuss patient perceptions of ctDNA testing.

Medical professionals explore methods for integrating circulating tumor DNA results with radiographic and pathologic findings to optimize patient care.

The panel examines a clinical scenario, detailing their approach to circulating tumor DNA testing, including turnaround times, and providing insights on patient counseling.

Shield, the first FDA-approved blood test for CRC screening, may offer convenient screening access for those who are at average risk for the disease.

Daniel H. Ahn, DO, and Stacey A. Cohen, MD, discuss the COBRA clinical trial, which evaluated rates of ctDNA clearance in patients with colorectal cancer receiving assay-directed therapy.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, provide comprehensive insights on the DYNAMIC clinical trial, an interventional study of circulating tumor DNA in colorectal cancer.

Panelists analyze observed obstacles to implementing routine circulating tumor DNA testing as a standard of care, while offering strategies to overcome these challenges.

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

Jagoda Misniakiewicz, PharmD, discussed implementing fruquintinib into clinical practice and how it's mechanism of action compares with others in the space.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, discuss the role of circulating tumor DNA (ctDNA) as a biomarker in colorectal cancer and provide clinical insights on screening modalities.

The key opinion leaders share their approaches for communicating about circulating tumor DNA and minimal residual disease to patients, emphasizing the significance of ctDNA testing in detecting MRD.

Experts outline circulating tumor (ct) DNA analysis, detailing the two main techniques and their respective advantages and disadvantages.

The EA2201 trial assessed nivolumab plus ipilimumab and short-course radiation therapy for patients with locally advanced rectal cancer.

HRQOL data from the CheckMate 8HW trial may further support frontline nivolumab/ipilimumab for those with MSI-H or dMMR metastatic colorectal cancer.

Arvind Dasari, MD, MS, outlines the evolution of colorectal cancer screening, addressing historical challenges, and the development of non-invasive screening techniques.

Leading experts offer insights into colorectal cancer, including its prevalence, staging, and the current landscape of treatment options.

Data from FRESCO-2 support the approval of fruquintinib for those with previously treated metastatic colorectal cancer in the European Union.